PMID: 6414279Sep 22, 1983Paper

Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide

The American Journal of Cardiology
A Pottage

Abstract

New class I antiarrhythmic drugs differ in potency, adverse effects and pharmacokinetics. Encainide and flecainide can totally suppress arrhythmias in some patients, but arrhythmia induction can also occur. At effective dose levels, neurologic and gastrointestinal adverse effects are uncommon. Flecainide pharmacokinetics are suitable for oral use but encainide disposition is complex with variable bioavailability and active metabolites that contribute substantially to activity. Lorcainide is also potent, but neurologic adverse effects are common and dose-dependent bioavailability and an active metabolite may complicate long-term oral therapy. Tocainide and mexiletine can suppress arrhythmias in acute myocardial infarction, during convalescence from myocardial infarction and in patients with arrhythmias resistant to other therapy. Dose-related neurologic and gastrointestinal adverse effects are common, but hemodynamic effects are minor and arrhythmia induction is rare. Tocainide disposition is reasonably predictable and stable in patients, but mexiletine disposition is less so because of variation in distribution and clearance. Although all of the newer agents have some disadvantages, their availability should increase the likeli...Continue Reading

References

Nov 1, 1979·European Journal of Clinical Pharmacology·H Kesteloot, R Stroobandt
Jan 1, 1979·Journal of Cardiovascular Pharmacology·R W CampbellD G Julian
Nov 16, 1978·European Journal of Clinical Pharmacology·G Cocco, C Strozzi
Sep 1, 1979·The American Journal of Cardiology·M SamiD C Harrison
Aug 1, 1979·European Journal of Clinical Pharmacology·U KlotzP Heimburg
Apr 1, 1978·Circulation·J L AndersonD C Harrison
May 1, 1978·Circulation·R A WinkleD C Harrison
Apr 1, 1978·The American Journal of Cardiology·E N MooreR A Moller
Aug 1, 1978·British Journal of Clinical Pharmacology·N P CampbellR G Shanks
Aug 1, 1978·The American Journal of Cardiology·L N HorowitzA Farshidi
Nov 15, 1978·European Journal of Pharmacology·J K GibsonA L Bassett
Dec 1, 1977·Circulation·R L WoosleyJ A Oates
Jan 1, 1982·European Journal of Clinical Pharmacology·P J PentikäinenH A Hiltunen
Dec 1, 1980·American Heart Journal·O NyquistK Schenck-Gustafsson
Dec 1, 1980·American Heart Journal·H R HornM D Young
Dec 1, 1980·American Heart Journal·M D YoungH G Vassallo
Apr 1, 1981·American Heart Journal·R L Engler, M LeWinter
Apr 1, 1981·The American Journal of Cardiology·P J Podrid, B Lown
Apr 1, 1981·Annals of Internal Medicine·G M PerlowR L Epstein
Jul 1, 1981·The American Journal of Cardiology·M SamiR F DeBusk
Nov 1, 1981·American Heart Journal·R A WinkleD Ross
Nov 1, 1981·Drugs·D L KeefeD C Harrison
Apr 1, 1982·The American Journal of Cardiology·W M JackmanE N Prystowsky
Apr 1, 1982·The American Journal of Cardiology·P J Podrid, B Lown
Jun 1, 1982·British Journal of Clinical Pharmacology·A T ElvinD Lalka
Feb 1, 1983·The American Journal of Cardiology·V LegrandH E Kulbertus
Aug 27, 1981·The New England Journal of Medicine·J L AndersonB Pitt
Sep 1, 1982·British Heart Journal·J A BellD W Holt
Apr 1, 1982·American Heart Journal·H K LuiD T Mason
Sep 1, 1982·British Journal of Clinical Pharmacology·D El AllafA Dresse
Dec 1, 1981·The American Journal of Cardiology·H J DuffR L Woosley

❮ Previous
Next ❯

Citations

May 1, 1986·Canadian Anaesthetists' Society Journal·D Roy
May 13, 1986·European Journal of Pharmacology·A A Kinnaird, R Y Man
Sep 11, 1987·European Journal of Pharmacology·A Tippe, E M Linderer
Mar 1, 1987·Current Problems in Cardiology·A C Cuetter, V J Ferrans
Nov 1, 1987·Mayo Clinic Proceedings·R W Kreeger, S C Hammill
Sep 1, 1989·Chest·R Goli-BijankiM H Sketch
Apr 4, 2017·British Journal of Pharmacology·Samantha C SalvageChristopher L-H Huang
May 5, 2005·Pacing and Clinical Electrophysiology : PACE·Hiroshi WatanabeYoshifusa Aizawa
May 1, 1989·Postgraduate Medicine·H SkluthJ Gums
Sep 2, 1999·Anaesthesia and Intensive Care·M A CorkeronL Dusci
Jan 1, 1986·Drug Intelligence & Clinical Pharmacy·A E Wehmeyer, R L Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.